Navigation Links
Daiichi Sankyo, Inc. Celebrates the Growth of Its U.S. Headquarters
Date:5/13/2009

Caren Franzini, CEO of New Jersey Economic Development Authority, highlights New Jersey's talented workforce and strategic location as factors for economic growth and prosperity

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that the company has recently completed a major renovation and build-out of the interior of its Two Hilton Court U.S. headquarters facility to accommodate its growing workforce, creating sole occupancy by DSI of the building's 186,000 square feet.

Daiichi Sankyo, which has been doing business in New Jersey for more than 12 years, commemorated this growth milestone with a celebration for all of its employees today at the Parsippany headquarters. Caren Franzini, CEO, New Jersey Economic Development Authority, and Bob Franks, president, HealthCare Institute of New Jersey, attended the celebration and addressed employees, thanking them for their years of commitment to the New Jersey community and patients worldwide.

New Jersey Governor Jon S. Corzine signed a state proclamation congratulating Daiichi Sankyo employees for their success, the expansion of the company headquarters and commitment to the state.

"Daiichi Sankyo has not only made important contributions to pharmaceutical science, but has provided welcomed support to the Parsippany community and the citizens of New Jersey," said Governor Corzine. "The pharmaceutical industry plays a critical role in the state's economy, which is particularly important to us right now during these difficult economic times. Daiichi Sankyo is an example of a global company that has leveraged the advantages that the State of New Jersey offers to drive business growth. We are proud that the company has laid its foundation in the Garden State and will continue its commitment to developing innovative medicines that create hope in patients' lives."

The U.S. headquarters facility houses Daiichi Sankyo's 480 Parsippany-based employees, including corporate offices and all functions that support the company's commercial operations. When completely staffed, the building will house approximately 600 employees. In addition, the company has a clinical development division in Edison, New Jersey that employs 350 people who oversee clinical trials being conducted around the world.

The company expanded its U.S. workforce over the past few years as it launched several products for the treatment of hypertension, lipid disorders and diabetes, and in anticipation of the continuing development of its robust pipeline of compounds for cardiovascular disease and oncology, including an antiplatelet agent currently under FDA review.

According to a 2008 report by the HealthCare Institute of New Jersey, drug industry employment in the state dropped by 600 jobs in 2007, but Daiichi Sankyo experienced a 100 percent increase in New Jersey personnel from 2007 - 2008 alone, and a 10-fold increase in employees since its first occupancy of 15,000 square feet at the headquarters building in 1997.

"We are very happy to have made New Jersey the site of our U.S. headquarters," said Joseph P. Pieroni, president and CEO, Daiichi Sankyo, Inc. "The state has a long history of supporting the pharmaceutical industry and offers a highly skilled workforce to help us stay competitive. We're pleased to be part of the Parsippany community, and to have partnered with our neighbors in supporting projects that are vital to the well-being of New Jersey residents," Pieroni added.

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator. The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico
2. Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program
3. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
4. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
5. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
6. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Celebrates Successful First Year
8. Home Care Delivered, Inc. Celebrates National Nurses Week 2009 in Recognition of America's 2.9 Million Registered Nurses
9. Healthcare Management Systems Celebrates 25 Years
10. Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer
11. Weston United Celebrates Mental Health Month on May 19th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Two residents from the ... a video designed to encourage lawmakers to protect Medicaid funding. , The ... Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy Schwarz, a couple who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology: